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Abstract
Metastasis results from a complex set of traits acquired by tumor cells, distinct from those 
necessary for tumorigenesis. Here, we investigate the contribution of enhancer elements to the 
metastatic phenotype of osteosarcoma. Through epigenomic profiling, we identify substantial 
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differences in enhancer activity between primary and metastatic tumors in human patients as well 
as near-isogenic pairs of high and low lung-metastatic osteosarcoma cells. We term these regions 
Metastatic Variant Enhancer Loci (Met-VELs). Met-VELs drive coordinated waves of gene 
expression during metastatic colonization of the lung. Met-VELs cluster non-randomly in the 
genome, indicating that activity of these enhancers and their associated gene targets are positively 
selected. As evidence of this causal association, osteosarcoma lung metastasis is inhibited by 
global interruptions of Met-VEL-associated gene expression via pharmacologic BET inhibition, 
by knockdown of AP-1 transcription factors that occupy Met-VELs, and by knockdown or 
functional inhibition of individual genes activated by Met-VELs, such as coagulation factor III/
tissue factor (F3). We further show that genetic deletion of a single Met-VEL at the F3 locus 
blocks metastatic cell outgrowth in the lung. These findings indicate that Met-VELs and the genes 
they regulate play a functional role in metastasis and may be suitable targets for anti-metastatic 
therapies.
Introduction
More than 90% of all cancer deaths are the result of tumor metastasis1. The physical process 
of tumor cell dissemination and metastatic colonization of distant secondary sites has been 
well described2. Whole genome sequencing studies have elucidated the evolutionary 
phylogeny of metastatic dissemination3,4, and gene expression studies have revealed many 
of the genes that mediate the progressive steps of metastasis and drive organ-specific 
colonization5–7. These studies suggest that adaptation of metastatic tumor cells to the 
microenvironments of their destination organs is accompanied by a shift in cell state through 
widespread changes in the transcriptional output of metastatic cell genomes. Whether the 
shift is driven by genetic or epigenetic factors, or a combination of both of these 
mechanisms is not yet clear.
During normal development, gene expression changes that accompany cell state transitions 
are driven by altered activity of gene enhancer elements8–10. Enhancers govern cell type-
specific expression programs and are defined by signature chromatin features including 
H3K4me1, H3K27ac, and DNase hypersensitivity11. Enhancers appear to be important in 
tumorigenesis as well. Previous studies have demonstrated that malignant transformation is 
accompanied by locus-specific gains and losses in enhancer activity across the epigenome, 
termed Variant Enhancer Loci (VELs)12,13. Others have shown that in many types of 
cancers, clusters of active enhancers called super-enhancers (SEs) mediate dysregulated 
expression of oncogenes14,15. Collectively, these studies suggest that aberrant enhancer 
activity is a key driver of tumor formation and maintenance.
Altered transcriptional programs play a role in metastatic tumor progression. In certain 
model systems, these transcriptional programs have been associated with metastatic 
colonization of specific secondary organs5–7,16. Recently, epigenetic changes have been 
associated with transcriptional changes during metastasis17. However, the contribution of 
gene enhancers to metastatic transcription is not well understood. Based on the knowledge 
that enhancers drive cell-state transitions during normal development and tumorigenesis, we 
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hypothesized that enhancers may play a similar role in the transition of cancer cells from one 
developmentally distinct tissue to another during metastatic progression.
Osteosarcoma is the most common primary malignancy of the bone with peak incidence in 
children and adolescents. Clinical outcomes for patients have not improved for 30 years and 
there are currently no approved targeted anti-metastatic therapies for osteosarcoma in wide 
clinical use18. More than 75% of osteosarcoma metastases occur at the secondary site of the 
lung, which is the cause of the overwhelming majority of osteosarcoma related deaths19. In 
this study, we leverage the knowledge that gene enhancer activity is the cornerstone of 
cellular phenotypes and cell type specific gene expression9,20 to gain new insight into the 
regulatory mechanisms that allow metastatic osteosarcoma cells to overcome the barriers to 
colonization encountered as these cells engage the lung microenvironment. Our studies 
establish that enhancer elements endow tumor cells with metastatic capacity and that 
targeted inhibition of genes associated with enhancer alterations, or deletion of altered 
enhancers themselves is sufficient to block metastatic colonization and proliferation.
Results
The Metastatic Phenotype of Human Osteosarcoma is Associated with Variant Enhancer 
Loci
We mapped the locations of putative enhancer elements genome wide through ChIP-seq of 
the canonical enhancer-histone marks, H3K4me1 and H3K27ac in matched primary tumors 
and lung metastases from five osteosarcoma patients. We also performed H3K4me1 and 
H3K27ac ChIP-seq, and DNase-seq on a panel of five well-characterized21 metastatic and 
non-metastatic human osteosarcoma cell line pairs representing three distinct mechanisms of 
metastatic derivation including in vivo selection, treatment with a mutagenic compound, and 
introduction of an oncogenic driver (Fig. 1a). Based on the previous finding that H3K4me1 
broadly correlates with both poised and active enhancers22,23, we used this histone mark for 
our initial comparisons.
We found thousands of regions where H3K4me1 signals showed at least a 3-fold difference 
in enrichment between conditions (Fig. 1b, 1c). The metastasis-associated gains and losses 
of the H3K4me1 signal were reminiscent of those that we previously identified in the setting 
of primary tumor development through comparisons of primary colon tumors and normal 
colon tissue, known as VELs12,13. In distinction, we now and herein term the regions that 
show differential enrichment of H3K4me1 between metastatic samples and non-metastatic 
controls Metastatic Variant Enhancer Loci, or Met-VELs. Enhancers defined by differential 
enrichment of H3K4me1 generally showed concordant changes in H3K27ac ChIP-seq 
signals and DNase-seq signals (Fig. 1d and Extended Data Fig. 1), indicating robust 
commissioning and decommissioning of active enhancer elements at these loci. Across all 
samples, we found that on average 9.3% of all enhancers in a given metastatic cell line or 
tumor were gained relative to controls while 16.4% of enhancers present in non-metastatic 
cell lines or primary tumors were lost (Fig. 1e).
We next assessed the degree of Met-VEL heterogeneity across the cohort (Fig. 1F). Met-
VELs were more concordant between two metastatic cell lines (MNNG and 143B, labeled 
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with asterisks) derived from a single parental cell line (HOS) than those derived from 
distinct parental cell populations (40.8% versus 0.2–9.3%, P < 0.001), suggesting that the 
specific enhancer elements that undergo activation and silencing is non-random and may be 
in part driven by the genetic and/or epigenetic makeup of the parental cell line. Met-VELs 
were heterogeneous among the remaining samples, with 23–69.1% showing overlap with at 
least one other sample, and 4.2–18.4% showing overlap with 2 or more samples. No Met-
VELs were common to all cell lines or tissue samples. The heterogeneity observed could be 
a result of different selective pressures between the experimental approaches used to derive 
the metastatic cell lines, and also heterogeneity in the selective process of metastasis in 
patients. Additionally, the genetic heterogeneity among primary osteosarcoma tumors may 
contribute to the epigenetic heterogeneity we observe in cell lines and tumors.
An initial survey of Met-VEL distributions revealed dense clusters at distinct regions across 
the epigenome often in the vicinity of individual genes, similar to super-enhancers 
(Extended Data Fig. 2a). This finding led us to hypothesize that enhancer activity in these 
regions was non-randomly acquired due to selective pressures incurred during the process of 
metastatic progression. We systematically tested this hypothesis and found numerous loci 
with Met-VEL counts significantly greater than expected by chance in all samples (clusters 
in exemplar pairs displayed in Fig. 1g and Extended Data Fig. 2b). Several of the genes 
associated with Met-VEL clusters in both primary human samples and in the cell lines have 
been previously implicated in tumor biology and/or progression. ANGPT1 is a TIE2 
receptor agonist that plays a crucial role in angiogenesis and is currently being studied as a 
therapeutic target in malignancy24. Growth hormone receptor (GHR)25,26, 
phosphodiesterase 10A (PDE10A)27, and tissue factor (F3), have all been previously 
implicated in tumor biology and/or progression. F3 is a well-described activator of normal 
blood coagulation. In the setting of cancer, F3 plays tumor-cell-endogenous roles in 
promoting tumor growth and metastasis in multiple cancers, but the mechanism underlying 
its activation is not fully defined28. All metastatic/non-metastatic cell line and primary/
metastatic tumor pairs studied showed evidence of non-random acquisition and loss of 
enhancer clusters (Extended Data Fig. 2c). On average across the cohort, 22% of all Met-
VELs were found to reside in Met-VEL clusters (Extended Data Fig. 2d).
Metastatic Variant Enhancer Loci (Met-VELs) Dynamically Modulate Gene Expression as 
Tumor Cells Engage the Lung Microenvironment
To investigate the role of Met-VELs in modulating gene expression during metastasis, we 
utilized an ex vivo mouse model of osteosarcoma lung metastasis29. In this model, we seed 
GFP-expressing tumor cells to the lungs of mice by intravenous injection and culture lung 
sections ex vivo. This approach allows us to track metastatic outgrowth of GFP-labeled 
tumor cells in real time and to assess dynamic changes in gene expression (Fig. 2a). We 
performed RNA-seq at both early (24-hours) and late (day 14) time points in three cell line 
pairs. We associated Met-VELs with predicted target genes using PreSTIGE30 and validated 
that >94.5% of predicted Met-VEL gene targets lie within the same topologically associating 
domains (TADs) as the corresponding enhancer. In all cases, genes associated with gained 
Met-VELs and Met-VEL clusters were generally expressed at higher levels in metastatic 
cells within the lung microenvironment than in their corresponding non-metastatic parental 
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cell lines while genes associated with lost Met-VELs and lost Met-VEL clusters were 
expressed at lower levels (Fig. 2b and Extended Data Fig. 3a, b). To investigate whether 
Met-VEL-associated gene sets represent a transcriptional program specifically modulated in 
the setting of metastasis, we compared expression across conditions. The degree of 
differential expression of Met-VEL associated genes in the parental vs. metastatic cells was 
greater in ex vivo lung culture than in standard in vitro culture conditions (Extended Data 
Fig. 4a, b) indicating that modulation of these transcriptional programs represents a cellular 
response to external cues from the lung microenvironment. Met-VEL associated gene sets 
showed little overlap (< 27%) with the most differentially expressed genes in each 
metastatic/non-metastatic cell line pair indicating that Met-VEL associated genes represent a 
distinct set from those likely to be identified by expression data alone (Extended Data Fig. 
4c, d).
Subsets of genes associated with gained Met-VELs became highly expressed within 24hrs of 
arrival of metastatic cells to the lung, others were only activated later during metastatic 
outgrowth, and a third subset were constitutively up-regulated (Fig. 2c and Extended Data 
Fig. 3c). We assessed these gene sets for functional enrichment, and found that the phasic 
waves of gene expression coordinated by Met-VELs during lung colonization are associated 
with distinct cellular functions (Fig. 2d and Extended Data Fig. 3e). We verified that gained 
Met-VEL genes upregulated in the ex vivo lung model are frequently elevated in 
osteosarcoma patient lung metastases relative to primary tumors (Fig. 2e) and many of the 
same gene sets are enriched in gained Met-VEL target genes in osteosarcoma lung 
metastases in patients (Extended Data Fig. 5), thereby verifying that the genes identified 
using the cell line models and the ex vivo approach are representative of those dysregulated 
in human patients.
We performed motif enrichment analysis and identified a number of commonly expressed 
TFs with enriched motifs in gained and lost Met-VELs across all three pairs analyzed. The 
most highly enriched motifs include many members of the AP-1 complex (JUN, JUNB, 
JUND, FOS, and FOSL1) (Fig. 2f and Extended Data Fig. 3d) which has been previously 
shown to play a key role in osteosarcoma metastasis31. Intriguingly, AP-1 motifs were 
enriched at both gained and lost Met-VELs. This finding suggests that Met-VELs likely alter 
the transcriptional programs mediated by AP-1 during osteosarcoma metastasis. We verified 
that FOS and FOSL1 are bound at gained Met-VELs by ChIP-seq (Fig. 2g).
Met-VEL Associated Gene Expression is Required for Metastatic Colonization
Based on the finding that gained Met-VELs have high levels of the activating histone mark 
H3K27ac and the knowledge that the BET-family protein, BRD4, is critical for 
transcriptional activation by H3K27ac-marked enhancers, we reasoned that BRD4 inhibition 
may interrupt Met-VEL gene expression and indeed metastasis. To test this hypothesis, we 
used the BRD4-inhibitor JQ1, which displaces BRD4 from H3K27ac-marked 
enhancers15,32. JQ1 has been shown to inhibit osteosarcoma primary tumor formation 
through its effects on both tumor cells and bone cells within the tumor microenvironment33. 
We found that JQ1 showed potent anti-proliferative effects on metastatic tumor cells 
growing in the lung microenvironment without affecting the surrounding normal lung tissue 
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(Extended Data Fig. 6a–c). The anti-proliferative effects were associated with selective 
suppression of gained Met-VEL target genes that are normally up-regulated in metastatic 
cells in response to cues from the lung microenvironment (Extended Data Fig. 6d, e). 
Intriguingly, JQ1 more potently suppressed gained Met-VEL genes than genes associated 
with super-enhancers (Extended Data Fig. 6f) that have previously been linked to JQ1’s anti-
tumor properties in other tumor models15,34,35.
The results of the JQ1 studies suggest that activation of gained Met-VEL genes is necessary 
for metastatic outgrowth. To further test this hypothesis, we conducted a functional in vivo 
RNAi assay. We constructed a custom shRNA library targeting 33 genes. This gene list 
included 20 genes associated with gained Met-VELs or Met-VEL clusters, 11 TFs with 
motifs enriched at Met-VELs, and 2 genes of interest from other ongoing studies. We cloned 
the shRNA library into a tetracycline-inducible lentiviral construct (LTREPIR, Fig. 3a) 
modified from a similar construct previously published36. Using a DsRed fluorescent 
reporter of shRNA induction, we show that this construct was robustly induced upon 
exposure to doxycycline and not leaky in the absence of doxycycline (Extended Data Fig. 7). 
We conducted parallel screens in vivo and in vitro to allow us to distinguish genes that 
specifically inhibit metastatic outgrowth in the in vivo microenvironment, or metastasis 
dependency genes, from genes whose inhibition reduces cellular growth independent of 
context (Fig. 3b). In the in vivo screen, transduced cells were delivered via tail vein injection 
into mice pre-treated with doxycycline. Mice were maintained on doxycycline throughout 
the 21-day course of the experiment. In the parallel in vitro screen, transduced cells were 
treated in culture with doxycycline for 21 days. At the conclusion of the experiment, induced 
cells actively expressing shRNA (DsRed+/GFP+) were sorted from mouse lungs or in vitro 
culture by FACS. DNA was isolated from these cells, along with uninduced cells from the 
initial population (input), and shRNAs were amplified, sequenced, and aligned to the 
reference shRNA sequences of the library to determine normalized representation of each 
shRNA.
We defined metastasis dependency genes as those whose knockdown inhibited in vivo 
metastasis significantly more than in vitro growth. First, shRNA representations in 
metastatic tumor cells were compared to input representations to identify shRNAs depleted 
from the population of cells during metastatic outgrowth in the lung (Fig. 3c). Genes that 
were targets of at least two unique shRNAs (the pool contained 3–4 shRNAs per gene) that 
inhibited metastatic outgrowth to a greater degree than all negative controls were defined as 
initial hits. Because we used a second filter for these hits in this screen and planned further 
functional validation experiments, we intentionally chose a relatively inclusive threshold for 
initial hit calling. We found that 13 of 33 genes (39%) included in our screen met this 
criterion. To determine if depletion of cells expressing these shRNAs was specific to 
metastasis, we compared the relative representations of hits in the in vivo induced population 
of cells to in vitro induced controls (Fig. 3d). Genes whose shRNAs were significantly more 
depleted in vivo than in vitro were considered metastasis dependency genes. 6 of the 13 
initial hits met this criterion (Extended Data Table 1). Metastasis dependency genes included 
four genes associated with gained Met-VEL clusters (F3, FBXO42, FLNA, and FOXO3) as 
well as two AP-1 complex TFs whose motifs are enriched in Met-VELs and were shown to 
bind at these enhancers (FOS and FOSL1). These results indicate that metastatic 
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colonization of the lung by osteosarcoma cells is dependent on expression of a subset of 
individual genes associated with gained Met-VEL clusters as well as AP-1 complex TFs 
likely to regulate Met-VEL transcriptional programs.
Among the Met-VEL genes, F3 emerged as a top candidate driver of metastasis in 
osteosarcoma. In the MG63.3 cell line, F3 was associated with a gained Met-VEL cluster 
containing the second highest gained Met-VEL count of the entire data set (Fig. 1g), 
suggesting that this locus was under particularly strong positive selection during metastatic 
derivation. Gained Met-VELs in the F3 cluster also showed higher levels of H3K27ac and 
DNase accessibility in MG63.3 cells compared to the parental MG63 cell line and chromatin 
conformation capture studies confirmed that these enhancers physically contact the 
transcription start site of F3 (Extended Data Fig. 8a). F3 was more highly expressed in 
MG63.3 cells during metastatic outgrowth than in the parental MG63 cells (Extended Data 
Fig. 8b). In addition, two other metastatic cell lines, MNNG and 143B, showed active 
enhancer signals at the F3 locus, similar to MG63.3 (Extended Data Fig. 8d) and expressed 
F3 at higher levels during metastatic outgrowth than their parental cell line (Extended Data 
Fig. 8b). To verify that elevated F3 transcript levels were recapitulated at the protein level 
and also not an artifact of ex vivo culture, we performed immunofluorescence analysis of 
lung metastases from a fully in vivo model of metastasis and confirmed that metastatic 
osteosarcoma cells expressed higher levels of F3 protein than non-metastatic cells (Fig. 4a, 
b). Quantification of F3 levels directly in human osteosarcoma patient samples showed that 
F3 was elevated in lung metastases relative to primary tumors (Extended Data Fig. 8c). 
Using a tissue microarray, we confirmed that F3 protein was highly expressed in lung 
metastases from human osteosarcoma patients. F3 was expressed in >50% of tumor cells in 
18/18 lung metastases and F3 showed strongly positive staining in 17/18 samples (Fig. 4c, d, 
Extended Data Fig 9).
To determine whether F3 upregulation in osteosarcoma lung metastases was a result of 
enhancer dysregulation, we analyzed the enhancer epigenomes of 10 pairs of patient-
matched primary and metastatic tumors. While we do not observe de novo creation of a 
sufficient number of gained Met-VELs at the F3 locus to meet criteria to be called a gained 
cluster, the locus has an enhancer cluster that in 9 out of 10 metastatic samples is called as a 
super-enhancer and ranks among the most enriched H3K27ac sites (Extended Data Fig 10a). 
Comparison of the super-enhancer landscapes across all samples showed that the F3 super-
enhancer was among the top 1.3% of super-enhancers enriched in lung metastases relative to 
primary tumors (P < 0.05). This was true when metastatic tumors were compared to primary 
tumors alone and when metastatic/non-metastatic cell lines were included in the analysis 
(Extended Data Fig 10b).
We further interrogated the enhancer profiles of these 10 paired samples and verified that 
common Met-VEL gene targets in cell lines often overlapped with common Met-VEL 
targets in primary patient samples (Table S2).
We next tested the functional contribution of F3 expression to the metastatic phenotype. We 
cloned two shRNAs targeting F3 that were not included in the RNAi assay into the 
tetracycline-inducible LTREPIR construct. Relative to uninduced control cells, F3 
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expression was reduced 44–63% 40hrs after induction of each shRNA (Extended Data Fig. 
11). F3 knockdown with these shRNAs did not affect the in vitro growth rate of metastatic 
MG63.3 or MNNG cells (Extended Data Fig. 12a), but significantly reduced metastatic 
outgrowth of these cells in ex vivo lung culture (Extended Data Fig. 12b, c), supporting the 
metastasis-specific role for F3 in this setting. F3 knockdown also significantly reduced 
metastatic outgrowth of osteosarcoma cells in vivo (Extended Data Fig. 12d, e) and 
substantially prolonged survival of mice injected with metastatic osteosarcoma cells (Fig. 
4e). To further test whether F3 knockdown reduces in vivo growth of metastatic cells 
generally or if this effect is specific to metastatic outgrowth of cells in the lung, we 
completed a spontaneous metastasis experiment using an orthotopic injection model. We 
found that F3 knockdown did not reduce primary tumor development or growth (Fig. 4f), but 
significantly inhibited metastasis, reducing average metastatic burden by 3.6 fold (Fig. 4g, 
h). While extensive GFP+ metastatic lesions were observed in control mice, lungs of mice in 
the F3 knockdown group were virtually devoid of metastatic lesions with only rare single 
GFP+ cells observable in most cases (Extended Data Fig. 13).
F3 is known to both induce blood coagulation by mediating the generation of the active form 
of factor X (FXa) and to promote cell survival and proliferation upon binding to activated 
factor VII via intracellular signaling mechanisms28. To determine the relative contributions 
of each of these functions to the pro-metastatic role of F3 we used monoclonal antibodies 
generated to inhibit each of these functions independently37. As expected, we found that 
MG63.3 cells produce more FXa in in vitro assays than MG63 cells (Fig. 4i). We confirmed 
that anti-coagulant Mab-5G9 robustly inhibited this activity while Mab-10H10, designed to 
prevent intracellular signaling, did not. We next tested the anti-metastatic effects of these 
antibodies in vivo. We co-injected MG63.3 cells with each of these antibodies or IgG control 
into the tail veins of mice and found that both inhibited metastasis, with Mab-5G9 showing a 
more pronounced effect (Fig. 4j,k). These results indicate that both the intracellular 
signaling and pro-coagulant functions of F3 contribute to metastatic progression, but that 
F3’s pro-coagulant activity is especially critical to metastatic success. Collectively, these 
results suggest that Met-VELs regulate expression of genes, such as F3, with critical 
functions during metastatic progression.
To directly test the role of Met-VELs in mediating the metastatic phenotype we employed 
transcription activator-like effector nuclease (TALEN) genome editing to excise one of the 
gained Met-VELs predicted to regulate F3 in the metastatic cells. We targeted a Met-VEL 
located in a particularly robust DHS site containing high levels of both H3K4me1 and 
H3K27ac (Fig. 5a). This site also showed high ChIP-seq enrichment of both FOS and 
FOSL1 AP-1 complex members. We generated a cell clone with homozygous deletion of 
this Met-VEL, verified by Sanger sequencing (Fig 5a). Edited and unedited control cells 
were then seeded to mouse lungs via tail vein injection and the growth of the cells was 
monitored in the lungs using the ex vivo metastasis assay. Quantification of F3 levels 24-
hours post-injection showed that F3 expression was reduced by 34% in the edited cells 
relative to unedited control cells (Fig. 5b, c). By day 5, lungs seeded with the F3 Met-VEL-
edited cells were nearly devoid of tumor cells, while extensive GFP+ metastatic lesions were 
observed in lungs seeded with the unedited cells (Fig. 5d). Quantification showed that 
deletion of this gained Met-VEL decreased metastatic burden by 78% (Fig. 5e).
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Discussion
While many of the genes responsible for metastatic progression have been identified across 
tumor types, the underlying mechanisms regulating expression of these genes are not well 
defined. Our studies demonstrate that altered enhancer activity is a fundamental mechanism 
by which tumor cells regulate gene expression during the dynamic process of metastasis, and 
thereby acquire metastatic traits. Through epigenomic profiling experiments, we identify 
enhancers that distinguish human osteosarcoma lung metastases from matched primary 
tumors and verify that these differences are also present in near-isogenic metastatic and non-
metastatic paired human osteosarcoma cell lines. Subsets of these enhancer changes occur in 
non-random clusters indicating that they were positively selected during the process of 
metastatic derivation. These results demonstrate that the metastatic phenotype is 
accompanied by a shift in the enhancer epigenome, similar to the enhancer shifts that occur 
as cells transition through successive stages of embryonic development8–10, or during 
conversion of a normal cell to the malignant state12,14,15. The findings suggest that the 
evolutionary selective forces encountered by tumor cells during metastasis act to shape the 
enhancer landscape of metastatically successful cancer cell populations. The result of this 
selection is a population of cells possessing all of the traits necessary to overcome the 
barriers to metastatic colonization at distant tissues. Indeed, we show that many genes 
previously associated with metastasis become dysregulated through alterations in enhancer 
activity.
We provide multiple lines of evidence that acquired enhancer changes in metastatic 
osteosarcoma cells are functional and relevant to the osteosarcoma metastatic phenotype in 
experimental models and human tissues. First, we show that Met-VEL genes are 
dynamically regulated as metastatic cells engage the lung microenvironment and proliferate. 
Second, we demonstrate that metastatic cell outgrowth in the lung can be mitigated with 
through BET inhibition, and that this effect is associated with selective suppression of genes 
that are normally activated by Met-VELs in the lung. Third, through in vivo functional 
RNAi-based assays, we demonstrate that the metastatic capacity of the osteosarcoma cells 
can be diminished by targeted inhibition of individual Met-VEL genes and associated AP1-
family transcription factors that likely regulate Met-VEL transcriptional programs. Using a 
fully in vivo spontaneous model of metastasis, we further verify that one such Met-VEL 
gene, Tissue Factor (F3), is a clinically relevant, bone fide metastasis dependency gene 
essential for metastatic colonization with no apparent advantage to growth of the primary 
tumor. Interrupting the signaling and pro-coagulant functions of F3 was sufficient to inhibit 
metastasis, shedding light on the biological role of this gene in the metastatic progression of 
osteosarcoma. Our genomic Met-VEL deletion experiments demonstrate that the loss of 
function of a single gained enhancer at the F3 locus is sufficient to impair metastatic 
colonization and subsequent outgrowth in mice, indicating that enhancer activation 
contributed to acquisition of the metastatic phenotype of these cells.
Our current model is that F3 upregulation via the aberrant activation of its enhancers is 
required for lung colonization by metastatic osteosarcoma cells. It is not yet clear whether 
neutralizing F3 after colonization would lead to regression of overt metastases. The current 
standard of care for osteosarcoma involves multiple cycles of neoadjuvant combination 
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chemotherapy before surgical removal of the primary tumor18. As such, there is a period of 
several months between the time of diagnosis and primary tumor control. This treatment 
period is critical as there is the continued potential for cells to leave the primary tumor and 
seed the lungs. We believe that the most clear therapeutic setting for F3 inhibition would be 
during this period of neoadjuvant therapy. The findings presented here may present a 
rationale for testing F3 inhibition in such a setting. Further studies are required to determine 
whether there may be clinical benefit from continued F3 inhibition after primary tumor 
control is achieved.
Collectively our findings indicate that altered enhancer activity is a driver of gene expression 
that is critical for tumor cells to overcome the barriers of distant tissue colonization during 
metastasis. It is well established that primary tumor formation is driven by a combination of 
genetic and epigenetic events38. With respect to metastasis, studies have shown that primary 
and matched metastatic tumors are broadly similar at the genetic level with no recurrent 
mutations identified in metastases that were not present in the primary tumor3,4,39–44. These 
studies suggest that primary tumors are likely already genetically equipped with the ability 
to metastasize. Further this implies that epigenetic processes may mediate the shift in cell 
state that accompanies metastatic progression, as proposed by others17,45–48. Consistent with 
this epigenetic hypothesis, we show that osteosarcoma metastasis is accompanied by a shift 
in epigenetic state at enhancer elements. While our findings are not mutually exclusive with 
genetic theories of metastatic progression, we find that positive selection of enhancer 
activity is a fundamental component of the metastatic phenotype.
Our findings add to growing evidence implicating epigenomic processes in metastasis. 
McDonald et al. recently showed that pancreatic cancer metastasis is associated with 
widespread changes in heterochromatin defined by H3K9/H4K20 methylation17. Denny et 
al. showed that differences in chromatin accessibility correlated with metastatic progression 
in NFIB-driven small cell lung cancer49. Most recently, Roe et al. showed that aberrant 
enhancer activity mediated by FOXA1 promotes metastasis in pancreatic cancer50. 
Collectively, these studies demonstrate that chromatin changes drive the metastatic 
phenotype across various cancers. Our findings are well aligned with these studies, but 
further implicate enhancer dysregulation as the basis by which cells acquire metastatic 
competence and demonstrate that such dysregulation presents an opportunity for the 
development of targeted anti-metastatic therapies, as illustrated at the F3 locus.
Methods
Cell Culture
Human osteosarcoma cell lines were obtained and cultured as previously described21. 
MG63.3 cells were derived from MG63.2 (obtained from Dr. Hue Luu, University of 
Chicago, Chicago, IL) by metastatic selection in mice as previously described51.
The metastatic properties of these clonally related parental and metastatic cell lines have 
been thoroughly characterized in multiple murine models of metastasis21. A sample size of 5 
cell line pairs was chosen to capture the spectrum of methods of metastatic derivation and to 
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sufficiently power the study for comparative analyses based on similar studies completed by 
our lab in the past.
The purity and authenticity of all lines used in these studies has been independently 
confirmed by short tandem repeat (STR) profiling performed by the International Cell Line 
Authentication Committee. Mycoplasma testing was routinely performed with Mycoalert 
Mycoplasma detection kit (Lonza).
Mouse Studies
All animals were housed and handled in accordance with protocols approved by the CWRU 
IACUC or the NCI IACUC depending on location of performed studies. The number of 
animals included in each of the described studies was based on extensive past experience in 
the development and use of murine models of metastasis by our group. Each study was 
designed to minimize unnecessary animal use, optimize statistical power, and account for 
known variance in each model system. Within each experiment mice of the same strain, sex, 
and age were used for all conditions. At the initiation of each experiment mice were 
randomly assigned to cages and all mice in a given cage received equivalent treatment (e.g. 
doxycycline). Researchers were not blinded to the group assignments of mice as no 
subjective measurements were used.
Human Subjects
Osteosarcoma primary and lung metastatic tumors were obtained from the Laboratory of 
Experimental Oncology, Rizzoli Institute, Bologna, Italy with approval from Rizzoli 
Institute Ethics Committee. A waiver was granted for informed consent for patients deceased 
at the time of data collection according to the Data Privacy Regulation. Estimated tumor 
cellularity for samples ranged from 50–90%.
Ex Vivo Lung Metastasis Assay
Procedure for RNA Isolation—GFP-positive tumor cells (5 × 105) were delivered by tail 
vein injection to 8–10 week old female SCID/Beige (Charles River). Within 15 minutes of 
tumor cell injection, mice were euthanized with CO2 inhalation, and lungs were insufflated 
with a mixed agarose/media solution. Lung sections for ex vivo culture were generated as 
described29 and incubated at 37°C in humidified conditions of 5% CO2. Culture media was 
changed and lung sections were flipped every 2 days. Tumor cell RNA was harvested at 24hr 
and 14 day time points from one mouse for each condition. Lung sections were chopped into 
fine pieces and incubated in 3ml HBSS with 1mg/ml collagenase at 37°C for 30 minutes. 
EDTA was added to a final concentration of 10mM and the solution was placed on ice to 
stop digestion. Digested material was homogenized by passing through 18 ga needle 3–5x 
using 10 ml syringe. Homogenate was passed through a 70 micron cell strainer (Corning 
Life Sciences) and centrifuged at 500xg for 5 minutes at 4°C. Supernatant was aspirated and 
cells were re-suspended in 5ml ACK lysing buffer for 3 minutes at RT to lyse RBCs. Lysis 
was stopped by adding 10ml HBSS and cells were centrifuged at 500xg for 5 minutes at 
4°C. Supernatant was aspirated and cells were re-suspended in 2–3ml 0.5mM EDTA PBS 
and placed on ice. Immediately prior to sorting, cells were passed through a 40 micron cell 
strainer (Corning Life Sciences).
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Cells were sorted by FACS to isolate GFP+ tumor cells and immediately centrifuged at 
500xg for 5 minutes at 4°C. Supernatant was aspirated and cells were lysed in 1ml TRIzol 
reagent (Life Technologies), RNA was extracted with 200ul chloroform. Organic phase was 
isolated and 700ul of EtOH added. RNA was purified from this solution using the RNeasy 
Micro Kit (Qiagen).
Procedure for F3 Knockdown Studies—F3 knockdown cells were pretreated with 
5ug/ml doxycycline for 40hrs in standard culture. F3 shRNA induced cells were sorted by 
FACS to isolate DsRed+/GFP+ fraction. Uninduced control cells were sorted to isolate GFP
+ fraction. 2×105 cells were injected into the tail vein of each mouse. For F3 knockdown 
condition 5ug/ml doxycycline was added to agarose/media solution used to insufflate lungs 
as well as culture media. The medium was changed and fresh doxycycline was added every 
2 days. A total of 8 lung sections were imaged for each condition (4 sections per mouse, 2 
mice per condition).
Procedure for JQ1 Studies—5×105 tumor cells were injected into the tail vein of each 
mouse. For JQ1 treated cultures, medium was supplemented to a final concentration of 
250nM JQ1 by adding 10mM DMSO stock solution. Vehicle treated culture media was 
supplemented with DMSO volumes matching JQ1 treatment. Media was changed and fresh 
JQ1 or DMSO was added every 2 days. A total of 8 lung sections were imaged for each 
condition (4 sections per mouse, 2 mice per condition).
Assessment of Metastatic Burden—Lung sections were imaged by inverted 
fluorescent microscopy (Leica DM IRB) at a magnification of 2.5x. 2–3 images per lung 
section were taken to capture the entire surface of each section. Image analysis was 
performed using ImageJ software to quantify total GFP+ area per lung section. The 
metastatic burden was calculated by normalizing total GFP+ area to GFP+ area for each 
section on day 0. Values reported represent mean normalized tumor burden for all sections 
for each condition (8 sections per condition).
In Vitro RNA isolation
To match conditions used to isolate cells from ex vivo lung sections, cells growing in vitro 
were trypsinized and exposed to the same mechanical/enzymatic digestion conditions and 
sorted by FACS as described above. 5×105 GFP+ cells were collected and RNA was isolated 
as described above.
Code Availability
All custom code used for analysis in the current study are available from the corresponding 
author on reasonable request.
ChIP-seq
ChIPs were performed from 5–10×106 cross-linked cells and sequencing libraries were 
prepared as previously described52. The following antibodies were used for ChIP: rabbit 
anti-H3K4me1 (Abcam #8895), rabbit anti-H3K27ac (Abcam #4729), rabbit anti-c-Fos 
(Santa Cruz #sc-52), rabbit anti-FOSL1/Fra-1 (Santa Cruz #sc-605). ChIP-seq libraries were 
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sequenced on the HiSeq 2000 or 2500 platform at the Case Western Reserve University 
Genomics Core Facility.
Analysis was performed as previously described8.
Met-VEL Analysis
H3K4me1 ChIP-seq peaks were filtered to remove all peaks overlapping ENCODE 
blacklisted regions for functional genomics analysis (https://sites.google.com/site/
anshulkundaje/projects/blacklists) as well as peaks +/−1kb from transcription start sites 
(TSSs) of all annotated RefSeq genes to exclude promoters. Resulting peak lists of parental 
and metastatic cell line pairs were merged and RPKM values within merged peaks were 
calculated. Gained and lost Met-VELs were called as peaks with 3-fold increased or 
decreased RPKM values in metastatic cell lines relative to parental cell lines, respectively. 
To determine the fraction of differentially active enhancers in different cell types (Extended 
Figure 2), H3K4me1 ChIP-seq peaks for each pair of samples were filtered for ENCODE 
blacklisted regions and promoters, concatenated, and merged. Peak RPKMs were calculated 
for each sample in a pair and floored to 0.3. Differentially active enhancers were defined as 
those showing a 3-fold change in H3K4me1 signal in one sample relative to the other. The 
fractions of differentially active enhancers for the osteosarcoma tumors and cell lines panels 
were based on averages for each group.
Met-VEL Clustering Analysis
Global Met VEL distribution was assessed by calculating Met-VEL counts in 200kb sliding 
windows across all chromosomes. Met-VEL islands were defined as regions bordered by 
200kb windows with Met-VEL counts of 0. 200kb windows with maximum Met-VEL 
counts in each Met-VEL island were identified. To test for non-random Met-VEL 
distribution, the same analysis was performed on 1000 Met-VEL-size-matched H3K4me1 
peak lists randomly sampled from all H3K4me1 peaks in the cell line being analyzed to 
account for global enhancer distribution biases. Metastatic cell line H3K4me1 peaks were 
sampled to assess gained Met-VEL clustering. Parental cell line H3K4me1 peaks were 
sampled to assess lost Met-VEL clustering. The sampled lists were used to define expected 
distributions of random VEL acquisition in each cell line. Expected distributions were 
compared to observed distributions to test the null hypothesis of random Met-VEL 
acquisition. A p-value threshold of 0.05 was used to reject the null hypothesis in support of 
non-random acquisition of Met-VELs. 200kb windows with Met-VEL counts exceeding 
these thresholds were called as Met-VEL clusters.
Super-Enhancers (SEs)
Metastatic and parental cell line-specific SEs were identified from H3K27ac profiles using 
the ROSE software (retrieved from https://github.com/BradnerLab/pipeline). Analysis 
performed as previously described8.
RNA-seq
Gene expression profiles of cell lines grown in vitro were compared to expression profiles of 
the same cell lines at various time points during metastatic colonization using the ex vivo 
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pulmonary metastasis assay. RNA quality was assessed by 2200 TapeStation Instrument 
(Agilent). PolyA+ RNA was isolated using the Illumina TruSeq RNA Sample Preparation 
Kit according to the manufacturer’s protocol. RNA-seq libraries were sequenced on the 
Illumina HiSeq 2000 or 2500 platform at the Case Western Reserve University Next 
Generation Sequencing Core Facility.
Expression analysis was performed as previously described, aligning to the hg19 genome 
build8. FPKMs were quantile normalized across all samples.
Prediction of Gene Targets of Enhancers
Enhancer-gene assignments were made as described in30. To identify Met-VEL gene targets 
in patient tissues for which we did not have RNA-seq data, we used the GREAT software 
package59 to generate an initial list of candidate Met-VEL gene targets. We then further 
filtered this list by only including genes within the same TAD as the enhancer with a 
H3K27ac peak at their promoter, using a p-value cutoff of P < 1e-5. We then assessed 
overlaps in predicted Met-VEL gene targets between cell lines and patient tissues using the 
resulting gene lists.
Gene Ontology Analysis
Gained Met-VEL Gene Lists—Met-VEL gene lists were imported into gProfiler60 to 
generate enrichment scores for all GO, KEGG and REACTOME gene sets according to 
recommended settings for gProfiler http://baderlab.org/Software/EnrichmentMap/
GProfilerTutorial. Cytoscape (v3.2.1) and the Enrichment Map61 plug-in was used to 
generate networks for gene sets enriched with an FDR cutoff of < 0.05.
Lost Met-VEL Gene Lists—For gene ontology (GO) analysis, the genes associated with 
Met-VELs were analyzed using DAVID (http://david.abcc.ncifcrf.gov/home.jsp). A p-value 
of 10−3 was used as the threshold for significant enrichment of an ontologic category. 
Categories significantly enriched for gained or lost Met VEL genes in 2 or more pairs are 
reported, limiting overlapping lists to the three top scoring categories in each cell line (i.e. 
the categories with the lowest p-values).
DHS-seq
6.4–56×106 cells from each cell line were sequenced for DNase hypersensitivity (DHS) as 
previously described62. A 5′ phosphate added to linker 1B to increase ligation efficiency. 
After DNase concentrations were optimized for each line a total of approximately 1×106 
cells from optimally digested conditions were processed for sequencing. Libraries were 
sequenced on the HiSeq 2500 platform at the Case Western Reserve University Genomics 
Core Facility. Analysis was performed as previously described8.
Chromosome Conformation Capture Sequencing (4C-seq)
4C-seq sample preparation was performed as previously described63. NlaIII served as a 
primary restriction enzyme, DpnII as a secondary 4 bp-cutter. Primer sequences are provided 
in below. Amplified sample libraries were pooled and spiked with 40% PhiX viral genome 
sequencing library to increase sample diversity. Multiplexed sequencing was performed on 
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the MiSeq platform. Demultiplexing was performed by an in-house algorithm and all reads 
were hard trimmed to 36bp. Clipping of the primer sequences and data processing was 
performed using 4Cseqpipe Version 0.7 (retrieved from http://
compgenomics.weizmann.ac.il/tanay/?page_id=367). The viewpoint reads were aligned to a 
fragmented genome, as determined by the restriction site positions of the chosen primary 
and secondary restriction enzymes. A running linearly weighted mean, calculated in sliding 
windows of size 2–50KB, was used for signal smoothing of each genomic bin (size 16bp). 
Contact enrichment sites along the chromosomal axis were visually inspected.
Motif Analysis
To identify transcription factor (TF) motifs enriched in Met-VEL peaks, enhancers were 
centered on DNase hypersensitivity sites and the SeqPos module of the Cistrome tool was 
used to scan a 1kb window for enriched curated motifs64. Significantly enriched motifs in 
each cell line were then filtered using RNA-seq data and only expressed TFs were used for 
downstream analysis. Expressed TFs with enriched motifs in 3 out of 3 metastatic/parental 
cell line pairs (MG63.3/MG63; MNNG/HOS; 143B/HOS) are presented in the results.
In Vivo RNAi High-Throughput Functional Assay
Vector Construction—The Tet-ON lentiviral construct was made by modifying the 
previously published optimized shRNAmir, “miR-E”, pRRL backbone36. Briefly, this 
construct contains an optimized 3rd generation Tet-responsive element (T3G) and rtTA3 to 
potentiate a positive feedback loop, enhancing expression of the construct upon induction 
and reducing construct leakiness. The version of the construct that we modified contained a 
constitutive Venus reporter and an induced DsRed reporter of expression (LT3REVIR). The 
construct was modified using standard cloning techniques to replace the Venus reporter with 
a puromycin resistance element (renamed LT3REPIR) so that cells already constitutively 
expressing GFP could be selected for transduction.
shRNA Library Generation—shRNAs targeting 33 genes were selected from the 
transOMIC technologies shERWOOD-UltramiR shRNA library (3 to 4 shRNAs per gene). 
Cloning of shRNA into the backbone construct was performed on contract by transOMIC 
technologies. The following shRNA sequences included in the library are listed in 
Supplementary Table 3. Scores indicate shERWOOD metric of predicted potency of each 
shRNA as assigned by previously described algorithm65. NGS of #N/A indicates that the 
shRNA failed to clone into the lentiviral backbone.
Lentiviral Production—VSV-G pseudotyped lentivirus was generated with standard 
laboratory techniques. Briefly, shRNA-LT3REPIR plasmids were co-transfected with 
packaging vectors psPAX2 and pCI-VSVG (Addgene) into 293FT cells using Cal-Phos 
Mammalian Transfection Kit (Clontech). Individual supernatants containing virus were 
harvested at 48 and 72 h post-transfection and filtered with 0.45μm PVDF membrane 
(Millipore).
Lentiviral Transduction and Selection—Transduction of MG63.3 was performed via 
24hr exposure to lentivirus in the presence of 8ug/ml polybrene using conditions to achieve 
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>1000x coverage of each shRNA in the library. Infection rate estimated to be 0.135% and 
predicted to achieve predominantly one lentiviral integration per cell. Transduced and non-
transduced cells were then treated with 2ug/ml puromycin. Transduced cells were selected 
until all cells in non-transduced plate were dead (2–4days) to obtain a pure population of 
transduced cells (MG63.3i).
High-Throughput In Vivo Functional Assay—8–10 week old female SCID/Beige 
(Charles River) mice were used for the in vivo study arm. Mice were fed Dox Diet pellets 
containing 200mg/kg doxycycline (Bio-Serve) for 5 days prior to injection of cells. MG63.3i 
cells were pre-treated with 5ug/ml doxycycline for 12hrs in standard culture before being 
delivered to mouse lungs by tail vein injection. This primes the cells, but knockdown is not 
achieved even at the transcript level until 24–72 h after doxycycline addition. 1.5×106 cells 
were injected into each mouse (n=15). Mice were maintained on Dox Diet throughout the 
21-day course of the experiment. At the conclusion of the experiment mice were euthanized 
by CO2 inhalation and lungs were surgically extracted and homogenized using the Tumor 
Dissociation Kit, human (Miltenyi) according to the manufacturer’s protocol. Mouse lung 
cells were depleted using the Mouse Cell Depletion Kit (Miltenyi) according to the 
manufacturer’s protocol. Lungs from 5 mice were pooled for each replicate to achieve 1000x 
engraftment coverage of each shRNA in the library. GFP+/DsRed+ cells were then isolated 
by FACS.
Three replicates of 1.5×106 MG63.3i cells growing in vitro were induced with 5ug/ml 
doxycycline and maintained on doxycycline over 21 days in culture. GFP+/DsRed+ cells 
were isolated by FACS. Sorted cell counts of in vitro replicates were matched to numbers of 
cells isolated from the in vivo arm (3–5×105).
DNA was isolated from three replicates of uninduced MG63.3i cells as well as in vivo and in 
vitro arms of the experiment.
shRNA Amplification and Sequencing—Genomic DNA was isolated and sequenced 
as described66 with slight modification. Genomic DNA was isolated by two rounds of 
phenol extraction using PhaseLock tubes (5prime) followed by isopropanol precipitation. 
Deep sequencing libraries were generated by PCR amplification of shRNA guide strands 
using barcoded primers that tag the product with standard Illumina adapters. For each 
sample, DNA from at least 3 × 105 cells was used as template in multiple parallel 50-μl PCR 
reactions, each containing 1 μg template, 1× AmpliTaq Gold buffer, 0.2 mM of each dNTP, 
0.3 μM of each primer and 2.5 U AmpliTaq Gold (Applied Biosystems), which were run 
using the following cycling parameters: 95 °C for 10 min; 35 cycles of 95 °C for 30 s, 52 °C 
for 45 s and 72 °C for 60 s; 72 °C for 7 min. PCR products (340 nt) were combined for each 
sample, precipitated and purified on a 2% agarose gel (QIAquick gel extraction kit, Qiagen). 
Libraries were sequenced on the HiSeq 2500 platform at the Case Western Reserve 
University Genomics Core Facility. Libraries were sequenced using a primer that reads in 
reverse into the guide strand (miR30EcoRISeq, 
TAGCCCCTTGAATTCCGAGGCAGTAGGCA). To provide a sufficient baseline for 
detecting shRNA depletion in experimental samples, we aimed to acquire >1,000 reads per 
shRNA in all samples or 1.37×105 reads per sample. In practice, we achieved >2×106 reads 
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for all samples. Sequence processing was performed using two custom workflows using 
usegalaxy.org67. Workflow can be accessed by the following links: https://usegalaxy.org/u/
tyleremiller/w/shrna-pipeline1 and https://usegalaxy.org/u/tyleremiller/w/shrnastep2. For 
each shRNA and condition, the number of matching reads was normalized to the total read 
number per lane. This measure of normalized coverage was used for all downstream 
analyses.
Inducible Knockdown of Tissue Factor (F3)
shRNAs targeting tissue factor (F3) were selected from the transOMIC technologies 
shERWOOD-UltramiR shRNA library and cloned into the LT3REPIR as described in the 
preceding section. Cloning of shRNA into the backbone construct was performed on 
contract by transOMIC technolgies. The following shRNA sequences were tested:
Table 2-3
Hairpins used in F3 knockdown experiments
Gene Hairpin ID Sequence
F3 shF3A RLGH-DU16277 TGCTGTTGACAGTGAGCGATCAGAAGGAACAACACTTTCATAGTGAAGCCACAGATGTATGAAAGTGTTGTTCCTTCTGACTGCCTACTGCCTCGGA
F3 shF3B RLGH-DU14137 TGCTGTTGACAGTGAGCGCGCCAACAATTCAGAGTTTTGATAGTGAAGCCACAGATGTATCAAAACTCTGAATTGTTGGCTTGCCTACTGCCTCGGA
F3 shF3C RLGH-GU22081 TGCTGTTGACAGTGAGCGCCCGACGAGATTGTGAAGGATATAGTGAAGCCACAGATGTATATCCTTCACAATCTCGTCGGTTGCCTACTGCCTCGGA
Lentiviral Production—VSV-G pseudotyped lentivirus was generated with standard 
laboratory techniques. Briefly, shRNA-LT3REPIR plasmids were cotransfected with 
packaging vectors psPAX2 and pCI-VSVG (Addgene) into 293FT cells using Cal-Phos 
Mammalian Transfection Kit (Clontech). Individual supernatants containing virus were 
harvested at 48 and 72 h post-transfection and filtered with 0.45 μm PVDF membrane 
(Millipore).
Lentiviral Transduction and Selection—Transduction was performed via 24hr 
exposure to lentivirus in the presence of 8ug/ml polybrene. Transduced and non-transduced 
cells were then treated with 2ug/ml puromycin. Transduced cells were selected until all cells 
in non-transduced plate were dead (2–4days).
Assessment of Knockdown—Optimal shRNA induction was assessed and found to 
occur with 5ug/ml doxycycline treatment. MG63.3 cells transduced with shF3A, shF3B, and 
shF3C were treated with doxycycline for 40hrs, typsinized and sorted to isolate DsRed
+/GFP+ fraction. Uninduced cells were sorted for GFP+ fraction. RNA was extracted from 
1×106 cells and purified using the RNAeasy Micro kit (Qiagen) according to the 
manufacturer’s protocol. RNA quality was assessed by 2200 TapeStation Instrument 
(Agilent). cDNA was synthesized using the High Capacity RNA-to-cDNA kit (ABI) 
according to the manufacturer’s protocol. Knockdown efficiency was determined by RT-
qPCR for F3 using optimized TaqMan Gene Expression Assay primers and TaqMan Gene 
Expression Master Mix (Life Technologies).
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RT-qPCR was performed to quantify percent knockdown with induction of each hairpin 
relative to uninduced controls. Hairpins shF3A and shF3B showed the highest degree of F3 
knockdown and were chosen for use the remainder of these studies.
In Vivo Experimental Metastasis Model
8–10 week old female SCID/Beige (Charles River) mice were used for all experimental 
metastasis studies. For all in vivo experimental F3 knockdown studies, mice in the F3 
knockdown group were fed Dox Diet pellets containing 2gm/kg doxycycline (Bio-Serve) for 
5 days prior to injection of cells. F3 knockdown cells were pre-treated with 5ug/ml 
doxycycline for 24hrs in standard culture. F3 shRNA induced cells were sorted by FACS to 
isolate DsRed+/GFP+ fraction. Control cells were sorted to isolate GFP+ fraction.
End Point Assessment of Lung Metastasis—5×105 MG63.3 DsRed+/GFP+ or 
MG63.3 GFP+ cells were injected into the tail vein of each mouse (n=10 mice per 
condition). Mice in the F3 knockdown group were maintained on Dox Diet throughout the 
experiment. On day 7 or day 14 following injection 5 mice from each group were euthanized 
by CO2 inhalation. Lungs were insufflated with PBS and imaged by inverted fluorescent 
microscopy (Leica DM IRB) at a magnification of 2.5x. 5 images per lung were taken to 
assess metastatic burden in each mouse.
Image analysis was performed using ImageJ software to quantify total GFP+ area per image. 
The metastatic burden was calculated as the sum of the total GFP+ area in the 5 images from 
each mouse.
Survival Analysis—5×104 cells were injected into the tail vein of each mouse (n=5 mice 
per condition). Mice in the F3 knockdown group were maintained on Dox Diet throughout 
the experiment. All mice that died underwent complete necropsy examination and 
confirmation of metastasis.
Orthotopic Spontaneous Lung Metastasis Model
8–10 week old female NSG mice (Jackson) were used for spontaneous metastasis studies. 
Mice in the F3 knockdown group were given water supplemented with 2mg/ml doxycycline 
hyclate (Sigma) and 2% sucrose for 5 days prior to injection of cells. F3 knockdown cells 
were pre-treated with 5ug/ml doxycycline for 24hrs in standard culture. F3 shRNA induced 
cells were sorted by FACS to isolate DsRed+/GFP+ fraction. Control cells were sorted to 
isolate GFP+ fraction. 3×105 cells were injected orthotopically into the paraosseous region 
adjacent to the left proximal tibia. For the F3 knockdown group water was changed and 
fresh doxycycline was added twice weekly. Injection sites were monitored twice weekly for 
tumor formation.
Tumors became measureable on day 21 for all groups at which time tumors were measured 
in two dimensions twice weekly. Tumor volume was calculated as follows: volume (mm3) = 
3.14 × [long dimension (mm)] × [short dimension (mm)]2. Experiment was terminated 
following 21 days of tumor measurements (42 days after injections) and mice were 
euthanized by CO2 inhalation. Lungs were insufflated with PBS and imaged by fluorescent 
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microscopy at 2.5x using Leica DM 5500B light microscope with a Leica DFC 500 camera. 
5 images per lung were taken to assess metastatic burden in each mouse.
Image analysis was performed using ImageJ software. Micrometastases were defined as 
GFP+ lesions with diameter >25 pixels in images captured at 2.5x magnification. Number of 
micrometastases per image were manually counted. Total micrometastases for each lung 
were calculated as the sum of the total number of micrometastases in 5 images from each 
mouse.
In Vitro Assay for FXa Formation
Cells growing in vitro were pre-treated with 25μg/mL IgG control, Mab-10H10, or 
Mab-5G9 20 minutes prior to assay. Cells were washed in serum-free DMEM, and Xa 
generation over time was measured 30 minutes after the addition of 1nM FVIIa and 50nM 
FX using the chromogenic substrate Spectrozyme FXa.
Assessment of F3 Inhibiting Antibodies on Metastatic Progression
5×105 GFP+ MG63.3 cells were mixed with 500μg IgG control, Mab-10H10, or Mab-5G9 
and injected into the tail vein of 10–12 week old female SCID-beige mice (N>5 mice per 
group). Mice were sacrificed 14 days after injection and metastatic burden was assessed by 
whole lung fluorescent imaging (5 images per mouse). Metastatic burden was quantified as 
total GFP+ area per mouse.
F3 Lung Metastasis Staining
To assess the F3 expression in metastatic tumor cells in the lung at progressive time points, 
mice were injected with 1 × 106 cells (via tail vein) and were euthanized via CO2 inhalation 
at 24 hrs and 15 days post-injection. Lungs were harvested, formalin-fixed and paraffin 
embedded. For ex vivo lung metastasis staining, the protocol described above was followed 
and lung sections were fixed at 24hrs and 5 days post-injection. Tissue sections of lungs 
were cut at a thickness of 5 microns. Prior to immunostaining, paraffin sections were 
dewaxed with xylenes, and rehydrated with an ethanol series. For antigen retrieval, tissue 
sections were immersed 95°C Target Retreival Solution (DAKO) for 25 minutes. Tissue 
sections were permeabilized with 0.01% Triton-X in PBS for 10 minutes. Slides were rinsed 
with PBS and blocked with 4% BSA in PBS for 10 minutes. The following primary 
antibodies were used: F3 - Rabbit monoclonal IgG F3 antibody (ab151748, Abcam); GFP – 
Goat polyclonal IgG GFP antibody conjugated to FITC (ab6662, Abcam). Primary 
antibodies were diluted in 4% BSA 1:100 and slides were incubated in antibody solution at 
4°C overnight. Slides were rinsed and incubated with goat polyclonal IgG anti-rabbit IgG (H
+L) conjugated to Alexa 594 (A-11037, Life Technologies) diluted 1:200 in 4% BSA for 1hr 
in dark humidified slide chamber. Nuclei were visualized with DAPI (Sigma, 1ug/ml). 
Tissue sections were mounted on slides using anti-fade mounting medium (Vectashield).
Stained sections were imaged by fluorescent microscopy at 20 or 40x using Leica DM 
5500B light microscope with a Leica DFC 500 camera. Image analysis was performed using 
ImageJ software. F3 expression was computed within GFP+ metastatic tumor cell area.
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Tissue Array Staining and Scoring
A tissue microarray that we previously developed containing 20 osteosarcoma patient lung 
metastases68 was assessed for F3 expression. 18 of these 20 samples had cores of sufficient 
quality on the stained slide to be scored. For staining, paraffin was removed by 5 minute 
incubation in xylene bath x2 and rehydrated using step-down concentrations of EtOH. 
Antigen retrieval was performed by incubation in 1:10 dilution of Target Retrieval Solution 
(DAKO) in steamer for 25 minutes at 95°C. Cells were permeabilized with 0.01% Triton-X 
in PBS for 10 minutes. F3 immunohistochemical staining was performed using rabbit 
monoclonal IgG F3 antibody (ab151748, Abcam) and the EnVision+ System-HRP (Dako) 
according to the manufacturer’s protocol. Cover slips were mounted on slides using anti-
fade mounting medium.
The array was scored by the Director of Soft Tissue Pathology at the Cleveland Clinic and 
Learner Research Institute who was blinded to the sample type. Cores were scored based on 
the % of tumor cells in the core with positive staining for F3 (0=0%, 1+=1–25%, 2+=26–
50%, 3+=>50%) and the intensity of F3 staining in positive areas (low intensity staining, 
high intensity staining). Individual cores were excluded from the analysis if no tumor was 
present, tumor was predominantly necrotic, or core was falling off the slide.
Targeted Deletion of an F3 Met-VEL by Genome Engineering
Two TALEN dimers were designed to target the flanks of the Met-VEL in the F3 locus as 
indicated in Fig. 5a. TALEN dimers recognized the sequences 5′-
GACCAACTCACTTGAGCTGtgtggtttttcttCAGTGCACAATTGTGAAAT-3′ and 5′-
GAATCGACTGATCAAAGCacatgaactttttaaaaaaGAGTAATAAGTTTACTT-3′, where 
spacer elements are in lower case. TALEN constructs were assembled with adaptations of 
previously described protocols69,70. MG63.3 cells were grown in 6-well plate format to 70% 
confluence and transfected with 2.5 μg plasmid for each TALEN monomer using 
Lipofectamine 2000® (ThermoFisher Scientific) as per the manufacturer’s instructions. 
Cells were incubated for 48 h at 30°C and genomic DNA was subsequently harvested using 
QuickExtract™ DNA Extraction Solution (Epicentre) as recommended by the supplier. 
Efficient deletion of the F3 Met-VEL was confirmed by agarose gel electrophoresis of PCR 
products generated using primers 5′-GCAGTGCACAACCTGTACAAC-3′ and 5′-
TTGGCCAGGGTCATTATGTT-3′ (Integrated DNA Technologies) and high fidelity 
AccuPrime™ Taq DNA Polymerase (ThermoFisher Scientific). Single cell clones were 
derived by limiting dilution and genotypes were confirmed as described above. Enhancer 
deletion of clonal cell population used for functional metastasis experiments was confirmed 
by Sanger sequencing using the primer sequences listed above.
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Extended Data
Extended Data Figure 1. Met-VEL profiles of osteosarcoma patient lung metastases and human 
osteosarcoma cell lines
a, Aggregate plots showing H3K4me1 ChIP-seq and H3K27ac ChIP-seq signal +/− 3Kb 
from midpoints of gained and lost Met-VELs in paired patient lung metastases and primary 
tumors.
b, Aggregate plots showing H3K4me1 ChIP-seq, H3K27ac ChIP-seq and DNase-seq signal 
+/− 3Kb from mid-points of gained and lost Met-VELs in metastatic/parental human 
osteosarcoma cell lines.
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Extended Data Figure 2. Met-VEL clusters occur across metastatic cancers
a. UCSC browser view of H3K4me1 profiles in MG63.3 (metastatic) and MG63 (parental) 
cell lines illustrating an example of a gained (left) and lost (right) Met-VEL cluster. Met-
VELs identified by black bars. 200kb Met-VEL clusters highlighted in gray.
b. Genome-wide lost Met-VEL landscape for MG63.3 cell line. Rows represent scaled 
chromosomal coordinates. Peaks represent maximum gained Met-VEL counts in 200kb 
sliding windows. Predicted target genes for selected peaks are labeled.
c. Gained and lost Met-VEL cluster counts in patient lung metastases/primary tumors and 
metastatic/parental cell line pairs.
d. Percentage of total gained (top) and lost (bottom) Met-VELs within and outside of 
clusters in patient lung metastases/primary tumors and metastatic/parental cell line pairs.
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Extended Data Figure 3. Assessment of Met-VEL associated gene expression during metastatic 
colonization of the lung
a. Schematic of experimental design for assessment of Met-VEL gene expression in parental 
and metastatic cell lines in ex vivo lung metastasis model. Image adapted from 29.
b. Log2 quantile-normalized FPKM values for gained (left) and lost (right) Met-VEL and 
Met-VEL cluster genes in HOS/MNNG (top) and HOS/143B (bottom) cell line pairs. 
Asterisks indicate significant differences in FPKM distributions between parental and 
metastatic cell lines (* P<0.05; ** P<1E-3; *** P<1E-4). P-values calculated by Mann-
Whitney Test.
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c. Heatmap of up-regulated gained Met-VEL genes in HOS/MNNG (top) and HOS/143B 
(bottom) cell line pairs.
d. Expressed transcription factors with enriched motifs in lost Met-VELs in three metastatic/
parental cell line pairs and corresponding motif enrichment p-values.
e. Gene Ontology (GO) terms for lost Met-VEL genes in three metastatic/parental cell line 
pairs and corresponding p-values.
Extended Data Figure 4. Assessment of Met-VEL associated gene expression in vitro and in ex 
vivo lung culture
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a. Log2 fold-change in quantile-normalized FPKM values of gained Met-VEL genes in 
metastatic cell lines versus parental cell lines in various conditions. P-values calculated by 
Mann-Whitney Test.
b. Log2 fold-change in quantile-normalized FPKM values of lost Met-VEL genes in 
metastatic cell lines versus parental cell lines in various conditions. P-values calculated by 
Mann-Whitney Test.
c. Violin plots of log2(fold-change quantile-normalized FPKM values) distributions for gene 
sets in three metastatic cell lines relative to parental non-metastatic lines. Fold-change values 
for all expressed genes and gained Met-VEL gene sets represent comparisons of expression 
in metastatic lines at day 14 in ex vivo lung culture to non-metastatic lines at 24hrs. Fold-
change values for lost Met-VEL gene set represent comparison of expression in metastatic 
lines at 24hrs in ex vivo lung culture to non-metastatic lines at 24hrs.
d. Bar charts indicating overlap between gained (left) and lost (right) Met-VEL gene sets 
and top 1000 up- and down-regulated genes in corresponding conditions, respectively.
Extended Data Figure 5. Assessment of enriched functions of gained Met-VEL genes in 
osteosarcoma patient metastases
Enriched Map representation of all Gene Ontology (GO) terms for gained Met-VEL genes 
calculated by aggregating gene lists from two patient metastases (Lung Met 4 and Lung Met 
5).
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Extended Data Figure 6. Analysis of anti-metastatic and gene expression effects of BET 
inhibition with JQ1
a. Kinetics of metastatic outgrowth of MNNG (top) and 143B (bottom) metastatic cell lines 
in ex vivo lung culture with 250nM JQ1 or vehicle (DMSO) treatment. Metastatic burden 
measured as total GFP+ area per lung section normalized to GFP+ area on day 0. Values 
represent averages of 8 lung sections (4 sections per mouse x 2 mice) +/−SEM. P-value 
calculated by Mann-Whitney Test. Dashed line indicates time points chosen for RNA-seq 
studies.
b. Representative 2.5x images of vehicle (left) and 250nM JQ1 treated (right) lung sections 
at day 15. Lung sections outlined with dashed white line. Scale bar = 500μm.
c. 20X image of hematoxylin and eosin stained section of lung slice after 15 days in ex vivo 
culture treated with DMSO (top) and 250nM JQ1 (bottom) illustrating viable lung cells and 
architecture. Scale bar = 100μm.
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d. GSEA plots of 2-fold up-regulated gained Met-VEL gene sets in vehicle versus JQ1-
treated MNNG (left) and 143B (right) cells isolated from ex vivo lung culture. Cells isolated 
at time points indicated by dashed lines in Supplemental Figure 2–5a.
e. Log2 fold-change expression 2-fold up-regulated gained Met-VEL gene sets in vehicle 
versus JQ1-treated MNNG (left) and 143B (right) cells isolated from ex vivo lung culture at 
time points indicated by dashed lines in Extended Data Figure 7a relative to parental cell 
line.
f. Percent reduction in gene expression with 250nM JQ1 treatment of all genes up-regulated 
2-fold in metastatic cell lines relative to parental cell lines at sorting time points, lost Met-
VEL genes, gained Met-VEL genes 2-fold up-regulated relative to parental cell lines at 
sorting time points, up-regulated gained Met-VEL genes without SE genes, and all SE genes 
in MNNG and 143B cells growing in ex vivo lung culture sorted at time points indicated in 
Extended Data Figure 7a.
Extended Data Figure 7. Assessment of LT3REPIR shRNA construct induction and leakiness
a. Schematic of doxycycline-inducible LT3REPIR shRNA construct. Modified from 
(Fellmann et al., 2013).
b. Cytometric analysis of GFP and DsRed expression in GFP+ MG63.3 cells transduced 
with LT3REPIR construct at baseline (left) and 40hrs after exposure to 5ug/ml doxycycline 
(right).
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Extended Data Figure 8. Assessment of Tissue Factor (F3) dysregulation in metastatic 
osteosarcoma
a. IGV browser view of H3K27ac, H3K4me1, and DNase profiles at F3 gained Met-VEL 
cluster locus in MG63.3 (metastatic) and MG63 (parental) cell lines. Top of figure shows 
local contact profile analysis of F3 locus in MG63.3. In the top panel (main trend), the 
contact intensity (black line) is calculated by using a running mean analysis of normalized 
read counts with a 1kb sliding window. The 20th and 80th percentile are visualized as a gray 
trend graph. In the bottom panel, contact intensities are computed using linearly increasing 
sliding windows (scaled 2–50 kb) and are displayed as a color-coded heatmap of positive 4C 
signals (maximum of interaction set to 1). Local color changes are log-scaled to indicate 
changes of statistical enrichment of captured sequences, corresponding to the enhancer-
promoter interaction. Areas of significant contact highlighted.
b. Fold-change quantile normalized F3 FPKM values in 3 metastatic cell lines at 24hrs and 
14 days of metastatic outgrowth in ex vivo lung culture relative to parental line at 24hrs.
c. Tissue Factor (F3) relative expression in human patient primary tumors and lung 
metastases normalized to expression in normal osteoblasts.
d. IGV browser view of H3K27ac, H3K4me1, and DNase profiles at F3 gained Met-VEL 
cluster locus in MG63.3, MNNG, and 143B metastatic cell lines.
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Extended Data Figure 9. F3 expression in human osteosarcoma tumors
Immunohistochemical staining of F3 in human osteosarcoma lung metastases and primary 
tumors. Scale bars = 200μm.
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Extended Data Figure 10. Assessment of Tissue Factor (F3) Met-VELs in patient lung metastases
a. IGV browser views of the F3 locus showing H3K27ac ChIP-seq tracks of lung metastases 
from 10 osteosarcoma patients. Blue bars below each track correspond to super enhancers 
defined using the ROSE script. Hi-C defined topologically associating domains (TADs) are 
displayed below.
b. Volcano plot of 5571 total super enhancers detected in all osteosarcoma patient samples 
and cell lines used in this study. Points marked in red denote super enhancers meeting the 
threshold of significance (P < 0.05) for being gained or lost in metastatic samples. Points in 
grey denote super enhancers below the significance threshold. The F3 super enhancer is 
indicated by the arrow.
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Extended Data Figure 11. Assessment of F3 knockdown by RT-qPCR
a, Amplification plots and standard curves of GAPDH RT-qPCR using 0.2ng, 2ng, 20ng, and 
200ng of template cDNA demonstrating efficiency value of 100% and R2 value of 1.000. All 
Cq values used for quantification of GAPDH were confirmed to be within linear range of 
standards.
b, Amplification plots and standard curves of F3 RT-qPCR using 0.2ng, 2ng, 20ng, and 
200ng of template cDNA demonstrating efficiency value of 97.2% and R2 value of 0.999. 
All Cq values used for quantification of F3 were confirmed to be within linear range of 
standards.
c, Relative GAPDH expression in DsRed+ (induced) cells transduced with F3 shRNA 
constructs after 40hrs treatment with 5ug/ml doxycycline relative to uninduced controls 
(average of 3 replicates +/−SEM).
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d, Relative F3 expression normalized to GAPDH in DsRed+ (induced) cells transduced with 
F3 shRNA constructs after 40hrs treatment with 5ug/ml doxycycline relative to uninduced 
controls (average of 3 replicates +/−SEM).
Extended Data Figure 12. Assessment of F3 knockdown on metastatic osteosarcoma cell in vitro 
growth and lung colonization
a. Change in confluence relative to day 0 of MG63.3 (top) and MNNG (bottom) cells 
transduced with F3 shRNA constructs grown in standard culture conditions over 108hrs in 
the presence or absence of 5ug/ml doxycycline. Values represent averages from 6 plates +/− 
SD.
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b. Representative 2.5x images of from day 21 of ex vivo lung culture sections of GFP+ 
MG63.3 (left) and MNNG (right) cells transduced with F3 shRNA constructs untreated (top) 
or treated with 5ug/ml doxycycline (bottom). Lung sections outlined with dashed white line. 
Scale bar = 500μm.
c. Quantification of metastatic burden at day 21 of ex vivo lung culture sections of GFP+ 
MG63.3 (left) and MNNG (right) cells transduced with F3 shRNA constructs untreated (red) 
or treated (blue) with 5ug/ml doxycycline. Values represent averages +/−SEM from 8 
sections per condition (4 sections per mouse x 2 mice) normalized to the same section at day 
0. P-Value calculated by Mann-Whitney Test.
d. Representative 2.5x images of in vivo metastatic burden in untreated (left) or 
doxycycline-treated (right) mice receiving tail vein injection of 5×105 GFP+ MG63.3 cells 
transduced with shF3B construct. Scale bar = 500μm.
e. Quantification of in vivo metastatic burden in untreated (red) or doxycycline-treated (blue) 
mice receiving tail vein injection of 5×105 GFP+ MG63.3 cells transduced with shF3B 
construct. Values represent log2 of total GFP+ area per 2.5x field, black bars represent 
average +/− SEM (N= 5 mice per condition, 5 images per mouse). P-Value calculated by 
Mann-Whitney Test.
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Extended Data Figure 13. Assessment of lung metastatic burden at experimental end point of 
orthotopic spontaneous metastasis experiment with F3 knockdown
a. All images used for quantification of in vivo metastatic lesions in lungs 21 days after 
measureable tumor formation in untreated mice receiving orthotopic injection of 8×105 
MG63.3 cells transduced with shF3B construct (5 mice per condition, 5 images per mouse). 
Scale bar = 250μm.
b. All images used for quantification of in vivo metastatic lesions in lungs 21 days after 
measureable tumor formation in doxycycline-treated mice receiving orthotopic injection of 
8×105 MG63.3 cells transduced with shF3B construct (5 mice per condition, 5 images per 
mouse). Scale bar = 250μm.
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Extended Data Table 1
Candidate metastasis dependency genes identified by in vivo high-throughput RNAi 
functional assay.
Gene Inclusion Criteria Metastasis Specific?
BACH2 Enriched Motif N
DOCK4 Common Gained Met-VEL
Gained Met-VEL Cluster (MG63.3)
N
F3 Gained Met-VEL Cluster (MG63.3) Y
FBXO42 Gained Met-VEL Cluster (MNNG/143B) Y
FLNA Common Gained Met-VEL
Gained Met-VEL Cluster (MNNG/143B)
Y
FOS Enriched Motif Y
FOSL1 Enriched Motif Y
FOXO3 Gained Met-VEL Cluster (MNNG/143B) Y
GHR Gained Met-VEL Cluster (MG63.3) N
JUN Enriched Motif N
JUNB Enriched Motif N
RASSF2 Common Gained Met-VEL N
TMEM230 Common Gained Met-VEL N
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Figure 1. H3K4me1 ChIP-seq identifies metastatic variant enhancer loci (Met-VELs) and Met-
VEL clusters
a, Schematic representation of human tumor and metastatic human osteosarcoma cell line 
cohort.
b, UCSC browser views of H3K4me1 profiles from MG63.3 (metastatic) and MG63 
(parental) cell lines illustrating an example of gained (top) and lost (bottom) Met-VEL(s). 
Met-VELs are boxed in red.
c, Heatmap showing H3K4me1 ChIP-seq signal +/−5kb from H3K4me1 peak midpoints for 
all putative enhancers in MG63.3/MG63 pair sorted by differences in signal. Sub-panel 
shows heatmap for gained and lost Met-VELs alone.
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d, Aggregate plots showing H3K4me1 ChIP-seq and H3K27ac ChIP-seq signal +/− 3kb 
from mid-points of gained (left) and lost (right) Met-VELs for a representative matched 
primary/lung metastatic human tumor pair (top) and MG63.3/MG63 cell line pair (bottom). 
DNase-seq signal +/− 3kb from Met-VEL mid-points is also shown for the MG63.3 and 
MG63 cell lines.
e. Percentage of enhancers gained and lost in metastatic samples relative to primary tumors 
or non-metastatic cell lines.
f. Heatmap of fold change normalized RPKM in metastatic samples vs. primary tumor or 
non-metastatic cell lines for aggregated list of all gained and lost Met-VELs across all 
samples. H3K4me1 signal shown on the left, H3K27ac signal shown on the right. The 
samples from left to right are as follows M112, 143B, MNNG, MG63.3, LM7, Lung Met 1, 
Lung Met 2, Lung Met 3, Lung Met 4, Lung Met 5. Asterisks indicate 143B and MNNG 
samples.
g. Genome-wide gained Met-VEL landscape for human osteosarcoma metastatic tumor 
(Lung Met 4) and MG63.3 cell line. Rows represent scaled chromosomal coordinates. Peaks 
represent maximum gained Met-VEL counts in 200kb sliding windows. Predicted target 
genes for selected peaks are labeled.
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Figure 2. Met-VELs modulate gene expression during metastatic colonization of the lung
a. Schematic of experimental design for assessment of Met-VEL gene expression in parental 
and metastatic cell lines in ex vivo lung metastasis model. Image adapted from 29.
b. Log2 quantile-normalized FPKM values for gained (left) and lost (right) Met-VEL and 
Met-VEL cluster genes in MG63/MG63.3 cell line pair. Asterisks indicate significant 
differences in FPKM distributions between parental and metastatic cell lines (* P<0.05; ** 
P<1E-3; *** P<1E-4). P-values calculated by Mann-Whitney Test.
c. Heatmap of up-regulated gained Met-VEL genes in MG63/MG63.3 cell lines illustrating 
phasic expression pattern.
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d. Enriched Map representation of all Gene Ontology (GO) terms for three classes of gained 
Met-VEL responder genes calculated by aggregating gene lists from all three cell line pairs.
e. GSEA plot of up-regulated gained Met-VEL gene set compiled from three metastatic cell 
lines in human patient lung metastases versus primary tumors.
f. Expressed transcription factors with enriched motifs in gained Met-VELs in three 
metastatic/parental cell line pairs and corresponding motif enrichment p-values.
g. Aggregate plot of H3K4me1, FOS, and FOSL1 ChiP-seq signal at all gained Met-VELs in 
MG63.3 cell line.
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Figure 3. In Vivo high-throughput RNAi functional assay of candidate metastasis dependency 
genes
a. Schematic of doxycycline-inducible LT3REPIR shRNA construct. Modified from 36.
b. Schematic of experimental design for in vivo high-throughput functional assay of 
candidate metastasis dependency genes.
c. Volcano plot of relative abundance of shRNAs targeting 33 genes in GFP+/DsRed+ sorted 
osteosarcoma cells from doxycycline-treated mice (N=15 mice per replicate x 3 replicates) 
versus input cell population. 2nd most depleted shRNAs for each gene are plotted as well as 
negative and positive shRNA controls. Negative controls contained groups of 2–4 shRNAs.
d. Volcano plot of relative abundance of shRNAs targeting 13 genes meeting initial hit 
criteria (Fig. 3c) in GFP+/DsRed+ sorted osteosarcoma cells from doxycycline-treated mice 
(N=5 per replicate x 3 replicates) versus GFP+/DsRed+ sorted osteosarcoma cells treated 
with doxycycline in vitro. 2nd most depleted shRNAs for each gene are plotted as well as 
negative controls groups of 2–4 shRNAs.
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Figure 4. Tissue Factor (F3) mediates lung metastasis of osteosarcoma
a. In Vivo 2.5x images of GFP+ MG63 (parental) and MG63.3 (metastatic) cells in the lung 
24hrs following tail-vein injection of 1×106 cells. Sections stained for GFP, tissue factor (F3, 
red), and DAPI. Arrowheads indicate individual tumor cells within lung. Scale bars = 20μm.
b. Quantification of mean red pixel intensity within GFP+ (tumor) area in MG63 (parental) 
and MG63.3 (metastatic) cells 24hrs after tail-vein injection (N=15 images per condition).
c. Representative images of immunohistochemical staining of F3 in human osteosarcoma 
lung metastases (M), primary tumor (P), and omission control (OC). Tissue microarray 
contained 18 scoreable lung metastases of similar quality to those displayed.
d. Percentage of lung metastases with various levels of F3 positivity.
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e. Kaplan-Meier plot of untreated (red) and doxycycline-treated (blue) mice tail-vein 
injected with 5×104 GFP+ MG63.3 cells transduced with shF3B construct (N=5 mice per 
condition). P-value calculated by Gehan-Breslow-Wilcoxon Test.
f. Primary tumor growth in untreated (red) and doxycycline-treated (blue) mice receiving 
orthotopic injection of 8×105 GFP+ MG63.3 cells transduced with shF3B construct. Values 
represent averages +/−SEM (N=5 mice per condition). P-values calculated using student’s t-
test.
g. Representative 2.5x images of in vivo metastatic lesions in lungs 21 days after 
measureable tumor formation in untreated (left) and doxycycline-treated (right) mice 
receiving orthotopic injection of 8×105 GFP+ MG63.3 cells transduced with shF3B 
construct. Arrowheads indicate individual tumor cells within lung. Scale bar = 500μm.
h. Quantification of lung metastatic burden 21 days after measureable tumor formation in 
untreated (red) and doxycycline-treated (blue) mice receiving orthotopic injection of 8×105 
GFP+ MG63.3 cells transduced with shF3B construct (N=5 mice per condition, 5 images 
per mouse). P-values calculated using Mann-Whitney test.
i. Amount of activated factor X (FXa) formed in in vitro assay by MG63 (left) and MG63.3 
(right) cells treated with 25μg/mL IgG control, 10H10, or 5G9 antibodies for 20 minutes 
prior to the addition of FVIIa and FX to a final concentration of 100nM. FXa formation 
assessed 30 minutes after adding FX. P-values calculated using student’s t test with Welch’s 
correction.
j. Representative 2.5x images of in vivo metastatic lesions in lungs of mice 14 days after tail 
vein injection of 5×105 MG63.3 cells with 500μg of IgG, 5G9, or 10H10 antibodies. Scale 
bar = 500μm.
k. Quantification of lung metastatic burden 14 days after tail vein injection of 5×105 
MG63.3 cells with 500μg of IgG, 5G9, or 10H10 antibodies (N= at least 5 mice per 
condition, 5 images per mouse). P-values calculated using Mann-Whitney test.
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Figure 5. Deletion of single gained Met-VEL blunts F3 expression and mitigates lung metastasis 
of osteosarcoma cells
a. IGV browser view of region targeted for deletion with TALENs. Schematic shows 
strategy for 4,211bp deletion. Sanger sequencing shows resulting clonal homozygous 
deletion.
b. Representative 40x images of WT and Met-VEL deleted MG63.3 cells in the lung 24hrs 
after initiation of an ex vivo lung metastasis experiment. Scale bar = 50μm.
c. Quantification of mean red pixel intensity (F3 expression) within GFP+ (tumor) area for 
WT and Met-VEL deleted MG63.3 cells 24hrs after initiation of ex vivo lung metastasis 
assay (N= at least 20 images per condition, sections taken from N=3–5 mice per condition). 
P-value calculated by Mann-Whitney Test.
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d. Representative 2.5x images of WT (left) and Met-VEL deleted (right) lung sections at day 
5. Lung sections outlined with dashed white line. Scale bar = 500μm.
e. Quantification of metastatic burden at day 5 of ex vivo lung culture for GFP+ WT and 
Met-VEL deleted MG63.3 cells. Bars represent mean +/−SEM from at least 8 sections per 
condition (4 sections per mouse x 2–3 mice) normalized to the same section at day 0. P-
Value calculated by Mann-Whitney Test.
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Table 2-1
4C-seq primers
4C-seq Primers:
Forward Primer CTGTAAACTTGCCAAGCATG
Reverse Primer GGTCGCACAGGAGAAAGG
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Table 2-4
Probes used for F3 RT-qPCR
Gene Symbol TaqMan Gene Expression Assay Primer
F3 Hs01076029_m1
GAPDH Hs02758991_g1
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